Evaluating Treatment Options of EGFR Inhibitors

Multidisciplinary approaches, RNA-based next-generation sequencing, and patient-specific front-line treatment decisions are all important for curating effective NSCLC treatments.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Ivonescimab demonstrated a broad prolongation of PFS across various prespecified subgroups in patients with treatment-naïve, PD-L1–positive NSCLC.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

The observed safety profile of HA121-28 was similar to that of other multi-targeted RET tyrosine kinase inhibitors.

Combining pembrolizumab with pemetrexed met the primary end point of objective response rate in a phase 2 trial.